Figure 5.
Quantitative analysis of MAP levels after treatment with siRNAs. Control siRNA and siRNAs to MAP2, MAP1b, and tau were transfected into hippocampal neurons. Cultures were fixed 1, 3, and 5 d, respectively, after transfection and immunostained for each MAP to evaluate its level as a result of the siRNA. Immunofluorescence indicates depletion of MAP2, MAP1b, and tau in siRNA-treated neurons (b, d, f), compared with control siRNA-treated neurons (B, D, F), is shown. A, C, E, The quantification of total fluorescence intensity within the soma revealing the progressive loss of MAP2, MAP1b, and tau depletion by siRNA. By day 5, the loss of MAP2, MAP1b, and tau in siRNA treated neurons are 95, 99, and 99%, respectively. G, Western blot of whole-cell extracts probed with the MAP2, MAP1b, and tau Ab, confirming the protein-lowering effect. GAPDH was used as the internal control. Error bars represent SE.